These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10761169)

  • 21. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat blood in vitro.
    Dong MK; Gilbertsen RB
    Agents Actions; 1993; 39 Spec No():C99-101. PubMed ID: 8273600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040.
    Kezar HS; Kilpatrick JM; Phillips D; Kellogg D; Zhang J; Morris PE
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(10-12):1817-30. PubMed ID: 16438050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
    Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
    Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley L; Sawyer J
    Clin Drug Investig; 2006; 26(5):279-86. PubMed ID: 17163261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of orally administered fudosteine in healthy Chinese volunteers.
    Jiao HY; Zhang ZJ; Xu FG; Tian Y; Zhang BB; Chen Y
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):65-71. PubMed ID: 16898073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
    Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
    J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
    Conry RM; Bantia S; Turner HS; Barlow DL; Allen KO; LoBuglio AF; Montgomery JA; Walsh GM
    Immunopharmacology; 1998 Jul; 40(1):1-9. PubMed ID: 9776473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.
    Barbhaiya RH; Forgue ST; Gleason CR; Knupp CA; Pittman KA; Weidler DJ; Movahhed H; Tenney J; Martin RR
    Antimicrob Agents Chemother; 1992 Mar; 36(3):552-7. PubMed ID: 1622165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.